Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 16/20 | 0.58 |
| ▸ | EGFR | P00533 | 7/20 | 0.48 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.48 |
| ▸ | FECH | P22830 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.47 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6177843 | 0.92 | ERBB2 (0.56) | ERBB2EGFRERBB4FECHCDK8 | |
| SCHEMBL6175719 | 0.92 | ERBB2 (0.57) | ERBB2EGFRERBB4HDAC1HDAC6 | |
| SCHEMBL6171500 | 0.92 | ERBB2 (0.63) | ERBB2EGFRERBB4FECHCDK8 | |
| SCHEMBL6174991 | 0.92 | ERBB2 (0.60) | ERBB2EGFRERBB4FECHCDK8 | |
| SCHEMBL6174111 | 0.91 | ERBB2 (0.66) | ERBB2EGFRERBB4FECHCDK8 | |
| SCHEMBL4617460 | 0.91 | ERBB2 (0.59) | ERBB2EGFRERBB4FECHCDK8 | |
| SCHEMBL6174833 | 0.91 | ERBB2 (0.62) | ERBB2EGFRERBB4FECHCDK8 | |
| SCHEMBL6174409 | 0.90 | ERBB2 (0.62) | ERBB2EGFRERBB4FECHCDK8 | |
| SCHEMBL6173293 | 0.90 | ERBB2 (0.60) | ERBB2EGFRERBB4FECHCDK8 | |
| SCHEMBL4618703 | 0.90 | ERBB2 (0.62) | ERBB2EGFRERBB4FECHCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171386-A1 | Small molecules for the treatment of abnormal cell growth | PFIZER INC. | 2003-09-11 | — | — | US | claimed |
| EP-1292591-B1 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1465632-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030171386-A1 | Small molecules for the treatment of abnormal cell growth | PFIZER INC. | 2003-09-11 | — | — | US | disclosed |
| WO-2003049740-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171386-A1 | Small molecules for the treatment of abnormal cell growth | ERBB2, EGFR, ERBB3 | ERBB2 1/4885EGFR 2/4885ERBB4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.